PDF(Pubmed)
Abstract：
UNASSIGNED: Central retinal vein occlusion (CRVO) is a rare adverse effect related to the use of tyrosine kinase inhibitors (TKIs) in patients with metastatic malignancies, which has only been reported in several case reports.
UNASSIGNED: We reported the case series of three CRVO patients on regular regimens of TKIs as part of targeted therapies for metastatic malignancies, all of whom were otherwise healthy with no or well-controlled systemic conditions. All these patients received injections of intravitreal dexamethasone implant (IDI) and achieved a fluid-free macula at the end of the visit. In addition, we reviewed the existing literature on this subject and present here an updated analysis of the related TKIs, ocular presentation, treatment, and prognosis.
UNASSIGNED: All patients diagnosed with CRVO on TKIs received dexamethasone implant treatment and obtained a fluid-free macula. We would like to raise awareness among our colleague oncologists about the possibility of CRVO related to TKI use and the necessity for patients to be screened regularly by a retinal specialist.
UNASSIGNED: We reported the case series of three CRVO patients on regular regimens of TKIs as part of targeted therapies for metastatic malignancies, all of whom were otherwise healthy with no or well-controlled systemic conditions. All these patients received injections of intravitreal dexamethasone implant (IDI) and achieved a fluid-free macula at the end of the visit. In addition, we reviewed the existing literature on this subject and present here an updated analysis of the related TKIs, ocular presentation, treatment, and prognosis.
UNASSIGNED: All patients diagnosed with CRVO on TKIs received dexamethasone implant treatment and obtained a fluid-free macula. We would like to raise awareness among our colleague oncologists about the possibility of CRVO related to TKI use and the necessity for patients to be screened regularly by a retinal specialist.
摘要：
■视网膜中央静脉阻塞（CRVO）是与转移性恶性肿瘤患者使用酪氨酸激酶抑制剂（TKIs）有关的罕见不良反应，仅在几例病例报告中报告。
■我们报道了3例CRVO患者接受常规TKIs治疗作为转移性恶性肿瘤靶向治疗的一部分，所有这些人在其他方面都是健康的，没有全身疾病或全身疾病得到良好控制。所有这些患者都接受了玻璃体内地塞米松植入物（IDI）的注射，并在访问结束时获得了无液黄斑。此外,我们回顾了关于这一主题的现有文献，并在此介绍了相关TKIs的最新分析，眼部表现，治疗,和预后。
■所有在TKI上诊断为CRVO的患者都接受了地塞米松植入治疗，并获得了无液黄斑。我们希望提高我们的同事肿瘤学家对与TKI使用相关的CRVO的可能性以及视网膜专家定期筛查患者的必要性的认识。
■我们报道了3例CRVO患者接受常规TKIs治疗作为转移性恶性肿瘤靶向治疗的一部分，所有这些人在其他方面都是健康的，没有全身疾病或全身疾病得到良好控制。所有这些患者都接受了玻璃体内地塞米松植入物（IDI）的注射，并在访问结束时获得了无液黄斑。此外,我们回顾了关于这一主题的现有文献，并在此介绍了相关TKIs的最新分析，眼部表现，治疗,和预后。
■所有在TKI上诊断为CRVO的患者都接受了地塞米松植入治疗，并获得了无液黄斑。我们希望提高我们的同事肿瘤学家对与TKI使用相关的CRVO的可能性以及视网膜专家定期筛查患者的必要性的认识。
